Form 4: Indaptus Therapeutics Director Granted Stock Options

Indaptus Therapeutics, Inc. Director Anthony J. Maddaluna was granted 12,500 stock options with an exercise price of $0.33, vesting on June 10, 2026.

Summary

• Anthony J. Maddaluna, a Director of Indaptus Therapeutics, Inc. (INDP), was granted 12,500 stock options.
• The stock options have an exercise price of $0.33 per share.
• These options will vest and become exercisable on June 10, 2026.
• The expiration date for these stock options is June 10, 2035.
• Following this transaction, Mr. Maddaluna directly beneficially owns 12,500 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine compensation event that aligns the director's interests with shareholder value, which is generally viewed as a neutral to slightly positive development.

Positives

• The grant of stock options to a director aligns management's interests with shareholder value creation, as the options gain value if the stock price increases above the exercise price.

Future Outlook

This Form 4 reports an insider equity grant and does not contain forward-looking statements regarding the company's operational or financial outlook.

Industry Context

This filing is a standard insider transaction report (Form 4) and does not provide broader industry context or trends. It specifically details an equity grant to a director of Indaptus Therapeutics, Inc.

Related Party Transactions

• The grant of 12,500 stock options to Director Anthony J. Maddaluna constitutes a related party transaction, which is a common form of executive and director compensation designed to align interests with shareholders.

Stakeholder Impact

• Shareholders: The grant of stock options to a director can align the director's financial interests with the long-term performance of the company, potentially benefiting shareholders if the stock price appreciates.

Next Steps

• The stock options granted to Director Anthony J. Maddaluna will vest and become exercisable on June 10, 2026.

Key Dates

Keywords

Indaptus Therapeutics, INDP, Stock Option, Director, Insider Transaction, Form 4, Equity Grant, Beneficial Ownership